Submitted: 10 Nov 2018
Accepted: 02 Jan 2019
First published online: 09 Jan 2019
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - FireFox Plugin)

J Renal Inj Prev. 2019;8(2):122-126.
doi: 10.15171/jrip.2019.23
  Abstract View: 372
  PDF Download: 317


Hypertension in adult polycystic kidney disease: a narrative review

Sarah Mian 1, Yogesh Acharya 1, Ranjan Dahal 2 *

1 Avalon University School of Medicine, Curacao, Netherlands Antilles
2 Saint Peter’s University Hospital, New Jersey, USA
*Corresponding author: Ranjan Dahal, MD, Email: Email:


Autosomal dominant polycystic kidney disease (ADPKD) is an inherited renal disorder that impacts approximately 12 million worldwide. It is characterized by bilateral kidney enlargement and cystic growth. Hypertension (HTN) is a focal point in the management of ADPKD and is linked to a faster progression to end stage renal disease. Current novel therapies have proven to reduce the progression of renal damage. The ideal goal is to minimize risk through preventative studies and pharmacology to further increase life expectancy and quality. The purpose of this article is to highlight the importance of blood pressure management in ADPKD and review current literature to determine the most effective preventative pharmacotherapy.

Implication for health policy/practice/research/medical education:

1. Hypertension (HTN) is an important risk factor for progressive renal and extra-renal complications in adult polycystic kidney disease (ADPKD). 2. Ambulatory blood pressure monitoring is important as complications like left ventricular hypertrophy (LVH) can manifest even before the diagnosis of HTN. 3. HTN, if not treated early, will potentially lead to faster glomerular filtration rate (GFR) decline and end stage renal disease. 4. Although no overall benefit of one antihypertensive over other is established to prevent decline in GFR, angiotensin-converting enzyme inhibitor (ACE-I)/ angiotensin receptor blocker (ARB) is recommended at present. 5. There is a strong need for standardized guidelines for management of HTN in ADPKD.

Please cite this paper as: Mian S, Acharya Y, Dahal R. Hypertension in adult polycystic kidney disease: a narrative review. J Renal Inj Prev. 2019;8(2):122-126. doi: 10.15171/jrip.2019.23.

First name
Last name
Email address
Security code

Article Viewed: 372

Your browser does not support the canvas element.

PDF Downloaded: 317

Your browser does not support the canvas element.